1 option
Pharmacoeconomic review report : indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD) in patients experiencing "OFF" episodes while on a stable dose of levodopa. Safinamide has not been shown to be effective as monotherapy for the treatment of PD. Safinamide (Onstryv) (Valeo Pharma Inc.) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Parkinson's disease.
- Cost effectiveness.
- Physical Description:
- 1 online resource (110 pages) : illustrations
- Edition:
- Final (with redactions).
- Place of Publication:
- Ottawa (ON) : CADTH, 2020.
- Summary:
- Safinamide mesylate is a monoamine oxidase B (MAO-B) inhibitor used as an add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD) in patients experiencing OFF episodes while on a stable dose of levodopa. It is available as 50 mg and 100 mg tablets at a submitted price of
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.